유전성 혈관부종 치료제 시장 - 세계 산업 규모, 점유율, 동향, 기회, 예측, 약제 클래스별, 유통 채널별, 용도별, 지역별 부문, 경쟁(2020-2030년)
Hereditary Angioedema Therapeutics Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Drug Class, By Distribution Channel, By Application, By Region and Competition, 2020-2030F
상품코드:1691775
리서치사:TechSci Research
발행일:2025년 03월
페이지 정보:영문 183 Pages
라이선스 & 가격 (부가세 별도)
ㅁ Add-on 가능: 고객의 요청에 따라 일정한 범위 내에서 Customization이 가능합니다. 자세한 사항은 문의해 주시기 바랍니다.
한글목차
유전성 혈관부종 치료제 세계 시장 규모는 2024년에 43억 6,000만 달러로 평가되었고, 예측 기간 동안 72억 8,000만 달러에 달할 것으로 예상되며, 2030년까지 8.89%의 연평균 복합 성장률(CAGR)을 나타낼 것으로 예상됩니다.
세계 유전성 혈관부종 치료제 시장은 인지도 향상, 진단 능력 향상, 새로운 치료 옵션의 도입으로 인해 크게 성장하고 있습니다. 유전학 연구의 발전으로 조기에 정확한 진단이 가능해져 적시에 개입하고 질병을 더 잘 관리할 수 있게 되었습니다. 제약회사들은 단클론 항체 및 저분자 억제제를 포함한 표적 치료제 개발에 집중하여 장기적인 예방 및 급성기 치료 솔루션을 제공합니다. 유전성 혈관성 부종의 유병률 증가는 의료비 지출 증가 및 환자 지원 활동과 함께 시장 성장을 더욱 촉진하고 있습니다. 또한, 혁신적인 치료법에 대한 규제 당국의 승인과 피하 및 경구 치료 옵션의 출현은 환자의 복약 순응도와 편의성을 향상시켜 업계에 좋은 전망을 가져다주고 있습니다.
시장 개요
예측 기간
2026-2030년
시장 규모 : 2024년
43억 6,000만 달러
시장 규모 : 2030년
72억 8,000만 달러
CAGR : 2025-2030년
8.89%
급성장 부문
예방약
최대 시장
북미
강력한 신약 파이프라인과 R&D 투자 증가가 경쟁 구도를 형성하고 있습니다. 바이오 제약사들은 효능을 개선하고 부작용을 줄이며 투여 방법을 개선하는 차세대 치료법을 모색하고 있습니다. 정맥주사에서 피하주사 및 경구투여로의 전환은 표준 치료법을 변화시켜 환자와 의료진의 부담을 줄여주고 있습니다. 제약사, 연구기관, 환자 단체 간의 공동연구와 전략적 파트너십을 통해 의약품 개발이 가속화되고 있습니다. 급성기 치료에만 의존하지 않고 예방적 조치를 원하는 환자가 증가함에 따라 예방적 치료의 확대는 시장의 장기적인 지속성을 촉진할 것으로 예상됩니다.
Global Hereditary Angioedema Therapeutics Market was valued at USD 4.36 Billion in 2024 and is expected to reach USD 7.28 Billion in the forecast period with a CAGR of 8.89% through 2030. The global hereditary angioedema therapeutics market is experiencing significant expansion, driven by increasing awareness, improved diagnostic capabilities, and the introduction of novel treatment options. Advances in genetic research have enabled early and accurate diagnosis, allowing for timely intervention and better disease management. Pharmaceutical companies are focusing on developing targeted therapies, including monoclonal antibodies and small-molecule inhibitors, to provide long-term prophylaxis and acute treatment solutions. The growing prevalence of hereditary angioedema, coupled with rising healthcare expenditure and patient advocacy efforts, is further supporting market growth. Furthermore, regulatory approvals for innovative therapies and the emergence of subcutaneous and oral treatment options are enhancing patient adherence and convenience, creating a favorable outlook for the industry.
Market Overview
Forecast Period
2026-2030
Market Size 2024
USD 4.36 Billion
Market Size 2030
USD 7.28 Billion
CAGR 2025-2030
8.89%
Fastest Growing Segment
Prophylaxis
Largest Market
North America
A strong pipeline of novel drugs and increased investment in research and development are shaping the competitive landscape. Biopharmaceutical companies are exploring next-generation therapies that offer enhanced efficacy, fewer side effects, and improved administration methods. The shift from intravenous to subcutaneous and oral treatments is transforming the standard of care, reducing the burden on patients and healthcare providers. Collaborations and strategic partnerships between pharmaceutical firms, research institutions, and patient organizations are accelerating drug development and market penetration. The expansion of prophylactic treatments is expected to drive long-term market sustainability, as more patients seek preventive measures rather than relying solely on acute treatments.
Key Market Drivers
Advancements in Research and Development (R&D)
Advancements in Research and Development (R&D) have been pivotal in boosting the Global Hereditary Angioedema Therapeutics Market. Hereditary Angioedema is a rare genetic disorder characterized by debilitating and unpredictable swelling episodes that can be life-threatening. In recent years, the relentless pursuit of scientific knowledge and innovative therapies has transformed the landscape of HAE treatment.
One of the most significant drivers of market growth has been the breakthrough discoveries in understanding the underlying mechanisms of HAE. Researchers have delved deep into the genetic and biochemical aspects of the disease, leading to a more precise understanding of how it develops and progresses. This increased knowledge has paved the way for the development of targeted therapies that are specifically designed to address the root causes of HAE.
Monoclonal antibodies, in particular, have emerged as a revolutionary approach in HAE therapeutics. These monoclonal antibodies, such as lanadelumab and ecallantide, have been engineered to specifically inhibit the activity of proteins like plasma kallikrein, which play a critical role in HAE attacks. This precision in drug design has proven highly effective in preventing and managing HAE episodes, providing patients with newfound hope and relief from the burden of their condition.
Key Market Challenges
High Treatment Costs
The High treatment costs have emerged as a significant obstacle hindering the growth and accessibility of the Global Hereditary Angioedema Therapeutics Market. HAE is a rare genetic disorder characterized by recurrent and potentially life-threatening swelling episodes. While advancements in therapeutics have improved the quality of life for HAE patients, the exorbitant cost of these treatments poses a considerable challenge. The prohibitively high cost of treatment makes these life-saving therapies inaccessible to a substantial portion of HAE patients, especially those without comprehensive health insurance coverage. This leads to disparities in access to care, with only a fraction of those in need benefiting from the latest advancements in HAE therapeutics.
For individuals who manage to access HAE therapies, the financial strain can be overwhelming. Copayments, deductibles, and out-of-pocket expenses can quickly accumulate, potentially forcing patients to make difficult choices between their healthcare needs and other essential expenses.
Access to HAE treatments is even more challenging in regions with limited healthcare resources and lower income levels. This exacerbates global healthcare disparities, where patients in wealthier nations have greater access to cutting-edge treatments, while those in less affluent regions struggle to secure even basic care.
Key Market Trends
Personalized Medicine Approaches
Hereditary angioedema (HAE) is a rare genetic disorder characterized by recurrent episodes of severe swelling in various body parts, including the extremities, face, gastrointestinal tract, and airway. This condition is caused by mutations in the SERPING1 gene, leading to deficient or dysfunctional C1 inhibitor (C1-INH) proteins, which play a crucial role in regulating inflammatory pathways.
Personalized medicine has significantly advanced the management of HAE by tailoring treatments to individual genetic profiles and disease manifestations. The process begins with precise genetic testing to identify specific mutations in the SERPING1 gene, which helps determine the subtype of HAE a patient has. This accurate diagnosis is essential, as it guides the selection of targeted therapies that address the underlying pathophysiological mechanisms.
For instance, patients with Type I HAE, characterized by low levels of functional C1-INH, may benefit from C1-INH replacement therapies such as Berinert or Cinryze. These treatments work by supplementing the deficient protein, thereby preventing or reducing the frequency of swelling episodes. Conversely, patients with normal C1-INH levels but dysfunctional protein (Type II HAE) might respond better to therapies that inhibit the kallikrein-kinin pathway, such as lanadelumab (Takhzyro), a monoclonal antibody that targets plasma kallikrein to prevent bradykinin formation, a key mediator of swelling in HAE.
Key Market Players
Shire plc
Sanofi SA
Pharming Healthcare Inc.
Attune Pharmaceuticals
Adverum Biotechnologies
Arrowhead Pharmaceuticals
Ionis Pharmaceuticals
BioCryst Pharmaceuticals Inc.
CSL Behring.
CENTOGENE N.V
Report Scope:
In this report, the Global Hereditary Angioedema Therapeutics Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:
Hereditary Angioedema Therapeutics Market, By Drug Class:
C1 Esterase Inhibitor
Selective Bradykinin B2 Receptor Antagonist
Kallikrein Inhibitor
Other Drug Classes
Hereditary Angioedema Therapeutics Market, By Distribution Channel:
Hospital Pharmacy
Retail Pharmacy
Other Distribution Channels
Hereditary Angioedema Therapeutics Market, By Application:
Prophylaxis
On-demand
Hereditary Angioedema Therapeutics Market, By Region:
North America
United States
Canada
Mexico
Europe
France
United Kingdom
Italy
Germany
Spain
Asia-Pacific
China
India
Japan
Australia
South Korea
South America
Brazil
Argentina
Colombia
Middle East & Africa
South Africa
Saudi Arabia
UAE
Competitive Landscape
Company Profiles: Detailed analysis of the major companies present in the Global Hereditary Angioedema Therapeutics Market.
Available Customizations:
Global Hereditary Angioedema Therapeutics Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:
Company Information
Detailed analysis and profiling of additional market players (up to five).
Table of Contents
1. Product Overview
1.1. Market Definition
1.2. Scope of the Market
1.2.1. Markets Covered
1.2.2. Years Considered for Study
1.2.3. Key Market Segmentations
2. Research Methodology
2.1. Objective of the Study
2.2. Baseline Methodology
2.3. Key Industry Partners
2.4. Major Association and Secondary Sources
2.5. Forecasting Methodology
2.6. Data Triangulation & Validation
2.7. Assumptions and Limitations
3. Executive Summary
3.1. Overview of the Market
3.2. Overview of Key Market Segmentations
3.3. Overview of Key Market Players
3.4. Overview of Key Regions/Countries
3.5. Overview of Market Drivers, Challenges, Trends
4. Global Hereditary Angioedema Therapeutics Market Outlook
4.1. Market Size & Forecast
4.1.1. By Value
4.2. Market Share & Forecast
4.2.1. By Drug Class (C1 Esterase Inhibitor, Selective Bradykinin B2 Receptor Antagonist, Kallikrein Inhibitor, Other Drug Classes)
4.2.2. By Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Other Distribution Channels)
4.2.3. By Application (Prophylaxis, On-demand)
4.2.4. By Region
4.2.5. By Company (2024)
4.3. Market Map
4.3.1. By Drug Class
4.3.2. By Distribution Channel
4.3.3. By Application
4.3.4. By Region
5. Asia Pacific Hereditary Angioedema Therapeutics Market Outlook
5.1. Market Size & Forecast
5.1.1. By Value
5.2. Market Share & Forecast
5.2.1. By Drug Class
5.2.2. By Distribution Channel
5.2.3. By Application
5.2.4. By Country
5.3. Asia Pacific: Country Analysis
5.3.1. China Hereditary Angioedema Therapeutics Market Outlook
5.3.1.1. Market Size & Forecast
5.3.1.1.1. By Value
5.3.1.2. Market Share & Forecast
5.3.1.2.1. By Drug Class
5.3.1.2.2. By Distribution Channel
5.3.1.2.3. By Application
5.3.2. India Hereditary Angioedema Therapeutics Market Outlook
5.3.2.1. Market Size & Forecast
5.3.2.1.1. By Value
5.3.2.2. Market Share & Forecast
5.3.2.2.1. By Drug Class
5.3.2.2.2. By Distribution Channel
5.3.2.2.3. By Application
5.3.3. Australia Hereditary Angioedema Therapeutics Market Outlook
5.3.3.1. Market Size & Forecast
5.3.3.1.1. By Value
5.3.3.2. Market Share & Forecast
5.3.3.2.1. By Drug Class
5.3.3.2.2. By Distribution Channel
5.3.3.2.3. By Application
5.3.4. Japan Hereditary Angioedema Therapeutics Market Outlook
5.3.4.1. Market Size & Forecast
5.3.4.1.1. By Value
5.3.4.2. Market Share & Forecast
5.3.4.2.1. By Drug Class
5.3.4.2.2. By Distribution Channel
5.3.4.2.3. By Application
5.3.5. South Korea Hereditary Angioedema Therapeutics Market Outlook
5.3.5.1. Market Size & Forecast
5.3.5.1.1. By Value
5.3.5.2. Market Share & Forecast
5.3.5.2.1. By Drug Class
5.3.5.2.2. By Distribution Channel
5.3.5.2.3. By Application
6. Europe Hereditary Angioedema Therapeutics Market Outlook
6.1. Market Size & Forecast
6.1.1. By Value
6.2. Market Share & Forecast
6.2.1. By Drug Class
6.2.2. By Distribution Channel
6.2.3. By Application
6.2.4. By Country
6.3. Europe: Country Analysis
6.3.1. France Hereditary Angioedema Therapeutics Market Outlook
6.3.1.1. Market Size & Forecast
6.3.1.1.1. By Value
6.3.1.2. Market Share & Forecast
6.3.1.2.1. By Drug Class
6.3.1.2.2. By Distribution Channel
6.3.1.2.3. By Application
6.3.2. Germany Hereditary Angioedema Therapeutics Market Outlook
6.3.2.1. Market Size & Forecast
6.3.2.1.1. By Value
6.3.2.2. Market Share & Forecast
6.3.2.2.1. By Drug Class
6.3.2.2.2. By Distribution Channel
6.3.2.2.3. By Application
6.3.3. Spain Hereditary Angioedema Therapeutics Market Outlook
6.3.3.1. Market Size & Forecast
6.3.3.1.1. By Value
6.3.3.2. Market Share & Forecast
6.3.3.2.1. By Drug Class
6.3.3.2.2. By Distribution Channel
6.3.3.2.3. By Application
6.3.4. Italy Hereditary Angioedema Therapeutics Market Outlook
6.3.4.1. Market Size & Forecast
6.3.4.1.1. By Value
6.3.4.2. Market Share & Forecast
6.3.4.2.1. By Drug Class
6.3.4.2.2. By Distribution Channel
6.3.4.2.3. By Application
6.3.5. United Kingdom Hereditary Angioedema Therapeutics Market Outlook
6.3.5.1. Market Size & Forecast
6.3.5.1.1. By Value
6.3.5.2. Market Share & Forecast
6.3.5.2.1. By Drug Class
6.3.5.2.2. By Distribution Channel
6.3.5.2.3. By Application
7. North America Hereditary Angioedema Therapeutics Market Outlook
7.1. Market Size & Forecast
7.1.1. By Value
7.2. Market Share & Forecast
7.2.1. By Drug Class
7.2.2. By Distribution Channel
7.2.3. By Application
7.2.4. By Country
7.3. North America: Country Analysis
7.3.1. United States Hereditary Angioedema Therapeutics Market Outlook
7.3.1.1. Market Size & Forecast
7.3.1.1.1. By Value
7.3.1.2. Market Share & Forecast
7.3.1.2.1. By Drug Class
7.3.1.2.2. By Distribution Channel
7.3.1.2.3. By Application
7.3.2. Mexico Hereditary Angioedema Therapeutics Market Outlook
7.3.2.1. Market Size & Forecast
7.3.2.1.1. By Value
7.3.2.2. Market Share & Forecast
7.3.2.2.1. By Drug Class
7.3.2.2.2. By Distribution Channel
7.3.2.2.3. By Application
7.3.3. Canada Hereditary Angioedema Therapeutics Market Outlook
7.3.3.1. Market Size & Forecast
7.3.3.1.1. By Value
7.3.3.2. Market Share & Forecast
7.3.3.2.1. By Drug Class
7.3.3.2.2. By Distribution Channel
7.3.3.2.3. By Application
8. South America Hereditary Angioedema Therapeutics Market Outlook
8.1. Market Size & Forecast
8.1.1. By Value
8.2. Market Share & Forecast
8.2.1. By Drug Class
8.2.2. By Distribution Channel
8.2.3. By Application
8.2.4. By Country
8.3. South America: Country Analysis
8.3.1. Brazil Hereditary Angioedema Therapeutics Market Outlook
8.3.1.1. Market Size & Forecast
8.3.1.1.1. By Value
8.3.1.2. Market Share & Forecast
8.3.1.2.1. By Drug Class
8.3.1.2.2. By Distribution Channel
8.3.1.2.3. By Application
8.3.2. Argentina Hereditary Angioedema Therapeutics Market Outlook
8.3.2.1. Market Size & Forecast
8.3.2.1.1. By Value
8.3.2.2. Market Share & Forecast
8.3.2.2.1. By Drug Class
8.3.2.2.2. By Distribution Channel
8.3.2.2.3. By Application
8.3.3. Colombia Hereditary Angioedema Therapeutics Market Outlook
8.3.3.1. Market Size & Forecast
8.3.3.1.1. By Value
8.3.3.2. Market Share & Forecast
8.3.3.2.1. By Drug Class
8.3.3.2.2. By Distribution Channel
8.3.3.2.3. By Application
9. Middle East and Africa Hereditary Angioedema Therapeutics Market Outlook
9.1. Market Size & Forecast
9.1.1. By Value
9.2. Market Share & Forecast
9.2.1. By Drug Class
9.2.2. By Distribution Channel
9.2.3. By Application
9.2.4. By Country
9.3. MEA: Country Analysis
9.3.1. South Africa Hereditary Angioedema Therapeutics Market Outlook
9.3.1.1. Market Size & Forecast
9.3.1.1.1. By Value
9.3.1.2. Market Share & Forecast
9.3.1.2.1. By Drug Class
9.3.1.2.2. By Distribution Channel
9.3.1.2.3. By Application
9.3.2. Saudi Arabia Hereditary Angioedema Therapeutics Market Outlook
9.3.2.1. Market Size & Forecast
9.3.2.1.1. By Value
9.3.2.2. Market Share & Forecast
9.3.2.2.1. By Drug Class
9.3.2.2.2. By Distribution Channel
9.3.2.2.3. By Application
9.3.3. UAE Hereditary Angioedema Therapeutics Market Outlook
9.3.3.1. Market Size & Forecast
9.3.3.1.1. By Value
9.3.3.2. Market Share & Forecast
9.3.3.2.1. By Drug Class
9.3.3.2.2. By Distribution Channel
9.3.3.2.3. By Application
10. Market Dynamics
10.1. Drivers
10.2. Challenges
11. Market Trends & Developments
11.1. Recent Developments
11.2. Product Launches
11.3. Mergers & Acquisitions
12. Global Hereditary Angioedema Therapeutics Market: SWOT Analysis
